Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
77 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-09-04
Study Completion Date
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The new coronavirus SARS-CoV-2, causes the COVID-19 infection, which showed a form of neurovirulence involving the Central and peripheral Nervous Systems \[Baig et al, 2020\]. In a mouse model for human ACE2 expression, the virus entered the brain mainly through the olfactory bulb pathway \[Netland et al, 2008\], with an encephalic invasion uniformly lethal even with low viral doses and without lung involvement. The death of the animal was reasonably related to neuronal dysfunction/death in cardiorespiratory bone marrow centers, while the absence of ACE2 prevented severe encephalopathy.
Men has a highly frequency of severe and lethal COVID-19, and the observed gender difference could be related to the regulation of ACE2 receptor expression.
The ACE2 gene is encoded by a region of the X chromosome that escapes inactivation, so that women have an increased expression of this protein. The process of inactivation of the X chromosome includes DNA methylation with a decrease in the expression of genes that are affected by methylation. In This way an epigenetic mechanism could modulate the expression of ACE2 in a gender-specific way determining its levels and consequently its protective role.
Also in this regulatory context of ACE2 expression the role of microRNA (miRNA) could be very important. In fact, the untranslated 3' region (UTR) of ACE2 presents a binding sequence for miRNA miR-200c-3p that has been found at high levels of expression in cellular models infected with H5N1 influenza virus \[Liu et al, 2017\].
In addition, high plasma levels of miR-200c-3p were found in patients with severe pneumonia while ACE2 was reduced suggesting a regulatory role of this miRNA in ACE2 receptor expression \[Liu et al, 2017\]. Deficiency of 25 (OH)D is common among elderly and obese men (during winter and spring), highlighting the sex-specific difference observed in COVID-19 infection \[La Vignera et al, 2020\]. This vitamin, envolved in physical recovery \[Siotto et al, 2019\], and in the pathway of the renin angiotensin system, seems important to be assessed in ex-COVID-19 patients with stroke outcomes in admission and at the end of the rehabilitation process.
The study will consist in:
* Epigenetic study: evaluation of methylation of ACE2 promoter and miR-200c-3p levels.
* Biochemical analysis: the evaluation of levels of angiotensin II, ACE2 and Vitamin D.
* Correlation between rehabilitative outcome and biological markers
Men has a highly frequency of severe and lethal COVID-19, and the observed gender difference could be related to the regulation of ACE2 receptor expression.
The ACE2 gene is encoded by a region of the X chromosome that escapes inactivation, so that women have an increased expression of this protein. The process of inactivation of the X chromosome includes DNA methylation with a decrease in the expression of genes that are affected by methylation. In This way an epigenetic mechanism could modulate the expression of ACE2 in a gender-specific way determining its levels and consequently its protective role.
Also in this regulatory context of ACE2 expression the role of microRNA (miRNA) could be very important. In fact, the untranslated 3' region (UTR) of ACE2 presents a binding sequence for miRNA miR-200c-3p that has been found at high levels of expression in cellular models infected with H5N1 influenza virus \[Liu et al, 2017\].
In addition, high plasma levels of miR-200c-3p were found in patients with severe pneumonia while ACE2 was reduced suggesting a regulatory role of this miRNA in ACE2 receptor expression \[Liu et al, 2017\]. Deficiency of 25 (OH)D is common among elderly and obese men (during winter and spring), highlighting the sex-specific difference observed in COVID-19 infection \[La Vignera et al, 2020\]. This vitamin, envolved in physical recovery \[Siotto et al, 2019\], and in the pathway of the renin angiotensin system, seems important to be assessed in ex-COVID-19 patients with stroke outcomes in admission and at the end of the rehabilitation process.
The study will consist in:
* Epigenetic study: evaluation of methylation of ACE2 promoter and miR-200c-3p levels.
* Biochemical analysis: the evaluation of levels of angiotensin II, ACE2 and Vitamin D.
* Correlation between rehabilitative outcome and biological markers
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury
NCT02389647
Cerebral Ischemia
COMPLETED
First-in-man Study of the Cerebrovascular Interventional Procedural Control System
NCT05972252
Acute Ischemic Stroke
UNKNOWN
NA
Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Treatments to Improve Neurological Evolution and Functional Status of Stroke Patients.
NCT04795687
Ischemic Stroke
UNKNOWN
Blod Biomarkers for Stroke
NCT03941249
Stroke
UNKNOWN
Extracellular Vesicles as Stroke Biomarkers
NCT05370105
Stroke
Rehabilitation
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A new coronavirus was identified in December 2019 in Wuhan, China as the causative agent of "Severe Acute Respiratory Syndrome" (SARS-CoV-2), a viral lung infection indicated by the acronym COVID-19 (coronavirus disease 2019). By the end of January 2020, this rapidly spreading virus had already infected more than 100,000 people in several countries, leading the World Health Organization to declare a "global emergency" \[Wu et al 2020\]. The clinical manifestations of COVID-19 can vary from the common cold to more serious lung diseases such as those observed in the "Severe Acute Respiratory Syndrome" (SARS) of 2002-2003 and the "Middle East Respiratory Syndrome" (MERS) of 2011.
The Sars-Cov2 virus, like other RNA viruses, also showed a form of neurovirulence with consequent involvement in some patients of the Central Nervous System (CNS) and Peripheral Nervous System (SNP) \[Baig et al, 2020\].
Neurological symptoms in patients with COVID-19 infection fall into three categories:
1. neurological expressions of the symptoms of the underlying disease (headache, dizziness, dysfunction of consciousness, ataxia, epileptic manifestations and stroke)
2. symptoms of neuro-peripheral origin (hypo-ageusia, hyposmia, neuralgia);
3. symptoms of skeletal muscle damage, often associated with liver and kidney damage.
The first data on COVID-19 infection are in favor of neurological involvement in a variable percentage of cases with particular expression in more severe patients \[Mao et al, 2020\]. According to some authors, involvement of the nervous system may be partly responsible for respiratory impairment \[Yan-Chao et al, 2020\].
It should be noted that in the case of SARS-CoV infection, in a mouse model for human ACE2 expression, the virus had entered the brain mainly through the olfactory bulb pathway \[Netland et al, 2008\]. Encephalic invasion was uniformly lethal with further evidence that brain inoculation with low viral doses could be lethal even without lung involvement. The death of the animal was reasonably related to neuronal dysfunction/death in cardiorespiratory bone marrow centers and the histopathological picture was characterized by a minimal cellular infiltrate in the brain supporting the hypothesis of a transsynaptic viral dissemination. The absence of ACE2 prevented severe encephalopathy in the animal model. The structures selectively affected by neuronal death were the dorsal vagal complex (nucleus of the solitary tract, postremactic area, dorsal motor nucleus of the vagus).
On the other hand, trans-nasal invasion selectively interfered with thalamic, hypothalamic, amygdala nuclei. Some affected nuclei had no explanation in the connection (e.g. cochlear nuclei). The invoked mechanism of neuronal loss was that of a "flock" of cytokines (IL-6).
CNS/SNP and muscle involvement is present in COVID-19 patients and a careful interpretation of them is desirable. The hyposmia reported suggests a nasal infection route with direct access to the CNS. This pathway could be alternative to the respiratory and intestinal pathways and theoretically it could occur, as in some cases of SARS-COV, with mainly neurological symptoms.
Recently it has been reported that symptoms of corticospinal tract impairment have been observed in 67% of patients \[Helms et al, 2020\].
The epidemiological data collected so far indicate a substantial difference between men and women in clinical manifestations and SARS-CoV-2 infections. Specifically, a mortality rate among men has been found to be 73% in China \[Chen et al, 2020\], 59% in South Korea \[Korean society of infectious disease, 2020\] and 70% in Italy as reported by the Higher Institute of Health (ISS). In addition, the mortality rate is very dependent on the presence of comorbidities. In fact, in 45000 Chinese patients positive for COVID-19 the mortality rate went from 0.9% in those patients without comorbidity to 10.5%, 7.3% and 6.3% in those with cardiovascular disease, diabetes mellitus and hypertension, respectively \[Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020\].
In Italy, data provided by the ISS have documented a percentage of deaths around 2.1% in patients without comorbidity, a percentage that increases to 21.3%, 25.9% and 50.7% in those patients with one, two and three comorbidities, respectively.
Thus the gender and presence of comorbidities have been identified as key factors in the evolution of COVID-19.
In addition to pre-existing comorbidities, which, as already reported, are almost always present in patients with severe and lethal COVID-19 with greater frequency in men, the biological mechanisms are to be considered the main responsible for the observed gender difference.
A hypothesis that attempts to explain all these epidiemological data is based on the regulation of ACE2 receptor expression (Angiotensin Converting Enzyme 2).
ACE2 is an enzyme that degrades angiontensin II by generating angiotensin (1-7) which plays a protective role against damage caused by infection, inflammation and stress \[Vickers et al, 2002; Zisman et al, 2003\].
The SARS-CoV-2 virus penetrates the target cells of the respiratory system through the binding of its surface S protein (spike protein) to the ACE2 receptor reducing its expression.
In this way there is also a decrease in angiotensin levels (1-7) resulting in increased hypertension and lung failure \[Gurwitz et al, 2020\].
Therefore, it is important to consider the expression of ACE2 in those patients with hypertension, heart disease or diabetes when evaluating the different mortality rate in patients with these comorbidities.
In addition, gender-specific mortality could be precisely related to modulation of ACE2 expression. In fact, estrogens induce an increase in ACE2 receptor expression, suggesting that, at least in women of childbearing age, even after infection, this enzyme is able to perform its protective function, particularly towards the lungs. In men, it seems that androgenic hormones play a pathogenetic role in modulating the expression of cellular enzymes such as serine protease TMPSSR2, involved in the phases following the attack of the virus on the receptor, i.e. in the viral entry, promoting the spread of the infection in lung cells.
The ACE2 gene is encoded by a region of the X chromosome that escapes inactivation, thus supporting the hypothesis of an increased expression of this protein in women who would have the advantage of being protected from the complications and fatalities of COVID-19 infection.
The process of inactivation of the X chromosome includes DNA methylation and as a result there is a decrease in the expression of those genes that are affected by methylation. In This way an epigenetic mechanism could modulate the expression of ACE2 in a gender-specific way determining its levels and consequently its protective role.
Also in this regulatory context of ACE2 expression the role of microRNA (miRNA) could be very important. In fact, the untranslated 3' region (UTR) of ACE2 presents a binding sequence for miRNA miR-200c-3p that has been found at high levels of expression in cellular models infected with H5N1 influenza virus \[Liu et al, 2017\].
In addition, high plasma levels of miR-200c-3p were found in patients with severe pneumonia while ACE2 was reduced suggesting a regulatory role of this miRNA in ACE2 receptor expression \[Liu et al, 2017\].
Vitamin D reduces the risk of viral infections, especially respiratory infections as described in literature \[Martineau et al, 2016; Gruber-Bzura et al, 2018; Gombart et al, 2020; Grant et al, 2020\]. In fact, Vitamin D increases cellular immunity by reducing circulating cytokines induced by the innate immune system in response to viral infections \[Huang et al, 2020\].
Vitamin D deficiency or deficiency contributes to acute respiratory syndrome in which mortality increases with age and chronic comorbidities \[Vásárhelyi et al, 2011\]. This vitamin is a prohormone that has been shown to attenuate acute lipopolysaccharide-induced lung damage in mice by regulating the expression of components of the renin angiotensin system including ACE and ACE2, renin and angiotensin III \[Xu J, 2017; Tsujino et al, 2019\]. In these two months different research groups strongly suggested the need for an analysis on the correlations between vitamin D levels and COVID-19 infections \[Tian et al, 2020; Panarese et al, 2020; Marik et al, 2020\]. Serum concentrations of Vitamin D (25 (OH)D) tend to decrease with age, which may be determinant in COVID-19 infection due to case fatality rates (CFR) that increase with age.
Reasons include less time spent in the sun and reduced vitamin D production as a result of lower levels of 7-dehydrocholesterol in the skin \[Siotto et al, 2019\]. In addition, it has been pointed out that deficiency of 25 (OH)D is particularly common among elderly and obese men (post-menopausal women tend to control levels through Vitamin D supplements) especially during winter and spring, highlighting the sex-specific difference observed in COVID-19 infection \[La Vignera et al, 2020\].
Considering the importance of this vitamin also in physical recovery \[Siotto et al, 2019\], in addition to its role in the pathway of the renin angiotensin system, it seems important to assess serum levels in ex-COVID-19 patients with stroke outcomes in admission and at the end of the rehabilitation process.
In summary, epidemiological data collected in recent months in different countries around the world have shown how gender differences and the presence of comorbidities affect the mortality rate due to COVID-19. Our hypothesis is that biological factors could play an important role in determining the severity of the disease, in particular the ACE2 receptor could be the key element in the development of the differences in gender-related immune response.
Study objectives
Main objectives:
To study the molecular mechanism of regulation of ACE2 in relation to gender, in patients with NeuroCovid19 outcomes and in particular with stroke outcomes in Covid19, hospitalized in 3 rehabilitation facilities.
In particular they will be performed:
* Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
* Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
* Correlation between rehabilitative outcome and biological markers (epigenetic and biochemical) This project will study the molecular mechanisms underlying the regulation of ACE2 related to gender differences in patients post stroke in NeuroCOVID-19 (stroke) hospitalized in Rehabilitation facilities and the relationship between these variables and the rehabilitation outcome.
If the study showed the presence of molecular mechanisms capable of influencing recovery, we could identify rehabilitation pathways more tailored to the characteristics of the patient.
The Sars-Cov2 virus, like other RNA viruses, also showed a form of neurovirulence with consequent involvement in some patients of the Central Nervous System (CNS) and Peripheral Nervous System (SNP) \[Baig et al, 2020\].
Neurological symptoms in patients with COVID-19 infection fall into three categories:
1. neurological expressions of the symptoms of the underlying disease (headache, dizziness, dysfunction of consciousness, ataxia, epileptic manifestations and stroke)
2. symptoms of neuro-peripheral origin (hypo-ageusia, hyposmia, neuralgia);
3. symptoms of skeletal muscle damage, often associated with liver and kidney damage.
The first data on COVID-19 infection are in favor of neurological involvement in a variable percentage of cases with particular expression in more severe patients \[Mao et al, 2020\]. According to some authors, involvement of the nervous system may be partly responsible for respiratory impairment \[Yan-Chao et al, 2020\].
It should be noted that in the case of SARS-CoV infection, in a mouse model for human ACE2 expression, the virus had entered the brain mainly through the olfactory bulb pathway \[Netland et al, 2008\]. Encephalic invasion was uniformly lethal with further evidence that brain inoculation with low viral doses could be lethal even without lung involvement. The death of the animal was reasonably related to neuronal dysfunction/death in cardiorespiratory bone marrow centers and the histopathological picture was characterized by a minimal cellular infiltrate in the brain supporting the hypothesis of a transsynaptic viral dissemination. The absence of ACE2 prevented severe encephalopathy in the animal model. The structures selectively affected by neuronal death were the dorsal vagal complex (nucleus of the solitary tract, postremactic area, dorsal motor nucleus of the vagus).
On the other hand, trans-nasal invasion selectively interfered with thalamic, hypothalamic, amygdala nuclei. Some affected nuclei had no explanation in the connection (e.g. cochlear nuclei). The invoked mechanism of neuronal loss was that of a "flock" of cytokines (IL-6).
CNS/SNP and muscle involvement is present in COVID-19 patients and a careful interpretation of them is desirable. The hyposmia reported suggests a nasal infection route with direct access to the CNS. This pathway could be alternative to the respiratory and intestinal pathways and theoretically it could occur, as in some cases of SARS-COV, with mainly neurological symptoms.
Recently it has been reported that symptoms of corticospinal tract impairment have been observed in 67% of patients \[Helms et al, 2020\].
The epidemiological data collected so far indicate a substantial difference between men and women in clinical manifestations and SARS-CoV-2 infections. Specifically, a mortality rate among men has been found to be 73% in China \[Chen et al, 2020\], 59% in South Korea \[Korean society of infectious disease, 2020\] and 70% in Italy as reported by the Higher Institute of Health (ISS). In addition, the mortality rate is very dependent on the presence of comorbidities. In fact, in 45000 Chinese patients positive for COVID-19 the mortality rate went from 0.9% in those patients without comorbidity to 10.5%, 7.3% and 6.3% in those with cardiovascular disease, diabetes mellitus and hypertension, respectively \[Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020\].
In Italy, data provided by the ISS have documented a percentage of deaths around 2.1% in patients without comorbidity, a percentage that increases to 21.3%, 25.9% and 50.7% in those patients with one, two and three comorbidities, respectively.
Thus the gender and presence of comorbidities have been identified as key factors in the evolution of COVID-19.
In addition to pre-existing comorbidities, which, as already reported, are almost always present in patients with severe and lethal COVID-19 with greater frequency in men, the biological mechanisms are to be considered the main responsible for the observed gender difference.
A hypothesis that attempts to explain all these epidiemological data is based on the regulation of ACE2 receptor expression (Angiotensin Converting Enzyme 2).
ACE2 is an enzyme that degrades angiontensin II by generating angiotensin (1-7) which plays a protective role against damage caused by infection, inflammation and stress \[Vickers et al, 2002; Zisman et al, 2003\].
The SARS-CoV-2 virus penetrates the target cells of the respiratory system through the binding of its surface S protein (spike protein) to the ACE2 receptor reducing its expression.
In this way there is also a decrease in angiotensin levels (1-7) resulting in increased hypertension and lung failure \[Gurwitz et al, 2020\].
Therefore, it is important to consider the expression of ACE2 in those patients with hypertension, heart disease or diabetes when evaluating the different mortality rate in patients with these comorbidities.
In addition, gender-specific mortality could be precisely related to modulation of ACE2 expression. In fact, estrogens induce an increase in ACE2 receptor expression, suggesting that, at least in women of childbearing age, even after infection, this enzyme is able to perform its protective function, particularly towards the lungs. In men, it seems that androgenic hormones play a pathogenetic role in modulating the expression of cellular enzymes such as serine protease TMPSSR2, involved in the phases following the attack of the virus on the receptor, i.e. in the viral entry, promoting the spread of the infection in lung cells.
The ACE2 gene is encoded by a region of the X chromosome that escapes inactivation, thus supporting the hypothesis of an increased expression of this protein in women who would have the advantage of being protected from the complications and fatalities of COVID-19 infection.
The process of inactivation of the X chromosome includes DNA methylation and as a result there is a decrease in the expression of those genes that are affected by methylation. In This way an epigenetic mechanism could modulate the expression of ACE2 in a gender-specific way determining its levels and consequently its protective role.
Also in this regulatory context of ACE2 expression the role of microRNA (miRNA) could be very important. In fact, the untranslated 3' region (UTR) of ACE2 presents a binding sequence for miRNA miR-200c-3p that has been found at high levels of expression in cellular models infected with H5N1 influenza virus \[Liu et al, 2017\].
In addition, high plasma levels of miR-200c-3p were found in patients with severe pneumonia while ACE2 was reduced suggesting a regulatory role of this miRNA in ACE2 receptor expression \[Liu et al, 2017\].
Vitamin D reduces the risk of viral infections, especially respiratory infections as described in literature \[Martineau et al, 2016; Gruber-Bzura et al, 2018; Gombart et al, 2020; Grant et al, 2020\]. In fact, Vitamin D increases cellular immunity by reducing circulating cytokines induced by the innate immune system in response to viral infections \[Huang et al, 2020\].
Vitamin D deficiency or deficiency contributes to acute respiratory syndrome in which mortality increases with age and chronic comorbidities \[Vásárhelyi et al, 2011\]. This vitamin is a prohormone that has been shown to attenuate acute lipopolysaccharide-induced lung damage in mice by regulating the expression of components of the renin angiotensin system including ACE and ACE2, renin and angiotensin III \[Xu J, 2017; Tsujino et al, 2019\]. In these two months different research groups strongly suggested the need for an analysis on the correlations between vitamin D levels and COVID-19 infections \[Tian et al, 2020; Panarese et al, 2020; Marik et al, 2020\]. Serum concentrations of Vitamin D (25 (OH)D) tend to decrease with age, which may be determinant in COVID-19 infection due to case fatality rates (CFR) that increase with age.
Reasons include less time spent in the sun and reduced vitamin D production as a result of lower levels of 7-dehydrocholesterol in the skin \[Siotto et al, 2019\]. In addition, it has been pointed out that deficiency of 25 (OH)D is particularly common among elderly and obese men (post-menopausal women tend to control levels through Vitamin D supplements) especially during winter and spring, highlighting the sex-specific difference observed in COVID-19 infection \[La Vignera et al, 2020\].
Considering the importance of this vitamin also in physical recovery \[Siotto et al, 2019\], in addition to its role in the pathway of the renin angiotensin system, it seems important to assess serum levels in ex-COVID-19 patients with stroke outcomes in admission and at the end of the rehabilitation process.
In summary, epidemiological data collected in recent months in different countries around the world have shown how gender differences and the presence of comorbidities affect the mortality rate due to COVID-19. Our hypothesis is that biological factors could play an important role in determining the severity of the disease, in particular the ACE2 receptor could be the key element in the development of the differences in gender-related immune response.
Study objectives
Main objectives:
To study the molecular mechanism of regulation of ACE2 in relation to gender, in patients with NeuroCovid19 outcomes and in particular with stroke outcomes in Covid19, hospitalized in 3 rehabilitation facilities.
In particular they will be performed:
* Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
* Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
* Correlation between rehabilitative outcome and biological markers (epigenetic and biochemical) This project will study the molecular mechanisms underlying the regulation of ACE2 related to gender differences in patients post stroke in NeuroCOVID-19 (stroke) hospitalized in Rehabilitation facilities and the relationship between these variables and the rehabilitation outcome.
If the study showed the presence of molecular mechanisms capable of influencing recovery, we could identify rehabilitation pathways more tailored to the characteristics of the patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neurologic Manifestations
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Covid patients
Inpatients and outpatients admitted to the investigators' rehabilitation facility with covid symptoms
Robotic assisted intervention
Intervention Type
DEVICE
Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
epigenetic analyses
Intervention Type
GENETIC
Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
biochemical analyses
Intervention Type
DIAGNOSTIC_TEST
Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Robotic assisted intervention
Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Intervention Type
DEVICE
epigenetic analyses
Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
Intervention Type
GENETIC
biochemical analyses
Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT);
* NeuroCOVID19 stroke patients with double nasopharyngeal swab negative after 24 hours for SARS-Cov2.
* latency time within 6 months after stroke event;
* sufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent;
* NeuroCOVID19 stroke patients with double nasopharyngeal swab negative after 24 hours for SARS-Cov2.
* latency time within 6 months after stroke event;
* sufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent;
Exclusion Criteria
* behavioral and cognitive disorders that may interfere with the therapeutic activity;
* other orthopaedic or neurological complications that may interfere with the rehabilitation protocol;
* inability to understand and sign informed consent;
* other orthopaedic or neurological complications that may interfere with the rehabilitation protocol;
* inability to understand and sign informed consent;
Minimum Eligible Age
18 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Don Carlo Gnocchi Onlus
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Irene Giovanna Aprile
Md, PhD, Principal Investigator, Head of Rehabilitation Unit
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irene Aprile, MD,PHD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Fondazione Don Carlo Gnocchi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Don Carlo Gnocchi
Rome, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.
Reference Type
BACKGROUND
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
Reference Type
BACKGROUND
Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020 Apr 2;12(4):988. doi: 10.3390/nu12040988.
Reference Type
BACKGROUND
Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020 Jan 16;12(1):236. doi: 10.3390/nu12010236.
Reference Type
BACKGROUND
Gruber-Bzura BM. Vitamin D and Influenza-Prevention or Therapy? Int J Mol Sci. 2018 Aug 16;19(8):2419. doi: 10.3390/ijms19082419.
Reference Type
BACKGROUND
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
Reference Type
BACKGROUND
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4;382(23):2268-2270. doi: 10.1056/NEJMc2008597. Epub 2020 Apr 15. No abstract available.
Reference Type
BACKGROUND
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Reference Type
BACKGROUND
Jakovac H. COVID-19 and vitamin D-Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589. doi: 10.1152/ajpendo.00138.2020. No abstract available.
Reference Type
BACKGROUND
Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020 Mar 16;35(10):e112. doi: 10.3346/jkms.2020.35.e112.
Reference Type
BACKGROUND
La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D. Int J Mol Sci. 2020 Apr 22;21(8):2948. doi: 10.3390/ijms21082948.
Reference Type
BACKGROUND
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11.
Reference Type
BACKGROUND
Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? Med Drug Discov. 2020 Jun;6:100041. doi: 10.1016/j.medidd.2020.100041. Epub 2020 Apr 29. No abstract available.
Reference Type
BACKGROUND
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Kumar GT, Urashima M, Camargo CA Jr. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017 Feb 15;356:i6583. doi: 10.1136/bmj.i6583.
Reference Type
BACKGROUND
Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.
Reference Type
BACKGROUND
Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008 Aug;82(15):7264-75. doi: 10.1128/JVI.00737-08. Epub 2008 May 21.
Reference Type
BACKGROUND
Panarese A, Shahini E. Letter: Covid-19, and vitamin D. Aliment Pharmacol Ther. 2020 May;51(10):993-995. doi: 10.1111/apt.15752. Epub 2020 Apr 12.
Reference Type
BACKGROUND
Tian Y, Rong L. Letter: Covid-19, and vitamin D. Authors' reply. Aliment Pharmacol Ther. 2020 May;51(10):995-996. doi: 10.1111/apt.15764.
Reference Type
BACKGROUND
Tsujino I, Ushikoshi-Nakayama R, Yamazaki T, Matsumoto N, Saito I. Pulmonary activation of vitamin D3 and preventive effect against interstitial pneumonia. J Clin Biochem Nutr. 2019 Nov;65(3):245-251. doi: 10.3164/jcbn.19-48. Epub 2019 Sep 11.
Reference Type
BACKGROUND
Vasarhelyi B, Satori A, Olajos F, Szabo A, Beko G. [Low vitamin D levels among patients at Semmelweis University: retrospective analysis during a one-year period]. Orv Hetil. 2011 Aug 7;152(32):1272-7. doi: 10.1556/OH.2011.29187. Hungarian.
Reference Type
BACKGROUND
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
Reference Type
BACKGROUND
Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep. 2017 Nov;16(5):7432-7438. doi: 10.3892/mmr.2017.7546. Epub 2017 Sep 20.
Reference Type
BACKGROUND
Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003 Oct 7;108(14):1707-12. doi: 10.1161/01.CIR.0000094734.67990.99. Epub 2003 Sep 22.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDG_Acegender_2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Blood Extracellular Vesicles as Predictive Recovery Biomarker After Stroke and Brain Injury
NCT06871800
RECRUITING
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
NCT03268668
RECRUITING
The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
NCT07269288
NOT_YET_RECRUITING
A Novel Method for Determination of Thromboembolic Stroke Origin
NCT06961604
NOT_YET_RECRUITING
EARLY_PHASE1
Precision Medicine in Stroke
NCT05815836
COMPLETED
Wearable Devices for Secondary Prevention of Ischemic Stroke
NCT04282993
UNKNOWN
NA
Multiomics Targeting Microbiome Associated Changes in Stroke Patients (StrokeMicroBiomics)
NCT04315922
COMPLETED
Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke
NCT04189497
COMPLETED
PROgnostic Value of MicroParticles and Markers of Hemostasis in TIA and Ischemic Stroke
NCT05524506
COMPLETED
Multimodal Investigation of Intracranial Clot Environment
NCT04421326
RECRUITING
A Study of the Efficacy of the Code Stroke in Spain
NCT02647957
COMPLETED
NA
Role of the Endothelium in Stroke-like Episode Among CDG Patients
NCT03250728
COMPLETED
NA
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
NCT02014896
COMPLETED
Assessing Neurocognition After Cerebrovascular Intervention
NCT03344276
RECRUITING
NA
Screening Protocol for Patients With Stroke
NCT01021033
COMPLETED
Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke
NCT02204267
COMPLETED
NA
Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
NCT05760326
UNKNOWN
Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window
NCT04256096
UNKNOWN
PHASE3
Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19
NCT04895462
COMPLETED
Neuronal and Glial Biomarkers in Stroke
NCT02409043
COMPLETED
Endovascular Acute Stroke Intervention - Tandem OCclusion Trial
NCT04261478
RECRUITING
NA
NeuroCognition After Carotid Recanalization
NCT04219774
COMPLETED
PHASE2
Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke
NCT06170086
ACTIVE_NOT_RECRUITING
Covid-19 Epidemic on Acute Stroke Management
NCT04370197
UNKNOWN
Evaluation of Treated and Untreated Stroke
NCT00001840
COMPLETED